Company news from the 03/13/07 news brief

Share this article:
A New Jersey jury on Monday ordered Merck to pay $47.5 million in damages after finding the drugmaker’s Vioxx was responsible for a plaintiff’s heart attack. Merck said it intends to appeal the verdict and the damages. European database and software solutions provider Cegedim has announced plans to acquire sales, marketing solution provider Dendrite in a deal worth approximately $751 million. Dorland Global Corporation launched a new Web site at, featuring a blog by Dorland Global co-founder, Harry Sweeney, a longtime advertising agency veteran who also serves as chair of the Coalition for Healthcare Communications. The blog will feature guest diarists, including agency executives, clients and colleagues in the healthcare communications industry, according to a news release. Publicis Groupe has acquired sales, marketing and Prescription Drug Marketing Act (PDMA) compliance firm Pharmagistics. Financial terms of the deal were not disclosed. Pharmagistics, based in Somerset, NJ, offers four key services including distribution of samples and literature to pharmaceutical sales forces, direct marketing solutions (direct-to-practitioner), PDMA compliant sample accountability services and specialty logistical services. Pharmagistics will remain a separate unit with its own identity operating within Publicis Groupe's Publicis Healthcare Communications Group, a Publicis Groupe news release said.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...